Here , we present a novel approach for treating SCID that combines selective depletion of GvHD-inducing alpha/beta ( α/β ) T-cells from the haploidentical HSCT graft with a subsequent donor lymphocyte infusion ( DLI ) enriched for CD45RO + memory T-cells.